The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY
Regulatory awareness was not clearly associated with self-reported practice change
The survey did not establish a clear association between regulatory awareness and obstetricians’ and gynecologists’ self-reported change in clinical practice.
The regulatory-awareness reference category, specific regulatory issue, and timeframe are not available in this summary. As a cross-sectional survey, it cannot establish whether awareness caused practice change.
See the evidence
Regulatory awareness not associated with self-reported change in clinical practice
aOR 0.89 95% CI: 0.69-1.14
Cömert, Erhan Hüseyin et al.. Regulatory awareness, counseling priorities, and treatment choices in menopausal hormone therapy: a cross-sectional survey of obstetricians and gynecologists.. Menopause (New York, N.Y.). 2026.
Standard hormone therapy protocol use tracked with reported practice change
Standard hormone therapy protocol use, favorable views of compounded bioidentical hormone therapy, and prioritizing patient preference were associated with reported change. Menopause patient volume had no clear link.
These findings came from a cross-sectional survey of obstetricians and gynecologists. The factors’ reference categories, patient-volume unit, and timeframe are not available in this summary, so causation cannot be established.
See the evidence
Standard hormone therapy protocol use associated with reported practice change
aOR 1.50 95% CI: 1.05-2.14
Cömert, Erhan Hüseyin et al.. Regulatory awareness, counseling priorities, and treatment choices in menopausal hormone therapy: a cross-sectional survey of obstetricians and gynecologists.. Menopause (New York, N.Y.). 2026.
Favorable perceptions of compounded bioidentical hormone therapy associated with reported practice change
aOR 1.85 95% CI: 1.35-2.54
Cömert, Erhan Hüseyin et al.. Regulatory awareness, counseling priorities, and treatment choices in menopausal hormone therapy: a cross-sectional survey of obstetricians and gynecologists.. Menopause (New York, N.Y.). 2026.
Patient preference prioritization associated with reported practice change
aOR 1.21 95% CI: 1.06-1.38
Cömert, Erhan Hüseyin et al.. Regulatory awareness, counseling priorities, and treatment choices in menopausal hormone therapy: a cross-sectional survey of obstetricians and gynecologists.. Menopause (New York, N.Y.). 2026.
Higher menopause patient volume associated with reported practice change
aOR 1.01 95% CI: 1.00-1.01
Cömert, Erhan Hüseyin et al.. Regulatory awareness, counseling priorities, and treatment choices in menopausal hormone therapy: a cross-sectional survey of obstetricians and gynecologists.. Menopause (New York, N.Y.). 2026.
Regulatory awareness was not clearly associated with self-reported practice change
The survey did not establish a clear association between regulatory awareness and obstetricians’ and gynecologists’ self-reported change in clinical practice.
The regulatory-awareness reference category, specific regulatory issue, and timeframe are not available in this summary. As a cross-sectional survey, it cannot establish whether awareness caused practice change.
Standard hormone therapy protocol use tracked with reported practice change
Standard hormone therapy protocol use, favorable views of compounded bioidentical hormone therapy, and prioritizing patient preference were associated with reported change. Menopause patient volume had no clear link.
These findings came from a cross-sectional survey of obstetricians and gynecologists. The factors’ reference categories, patient-volume unit, and timeframe are not available in this summary, so causation cannot be established.
Study details & original results
Cömert, Erhan Hüseyin et al.. Regulatory awareness, counseling priorities, and treatment choices in menopausal hormone therapy: a cross-sectional survey of obstetricians and gynecologists.. Menopause (New York, N.Y.). 2026.
Regulatory awareness not associated with self-reported change in clinical practice
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
WHEN YOU WANT TO GO DEEPERRead the product labelsEach document’s wording, version, source and date checked.
PRODUCT LABEL STATUS
What each product’s current FDA label document says about its boxed warning — read from the label itself and checked against the version published on DailyMed. A product’s status here is a fact about its label document on the date shown, not a statement about a regulatory decision.
How to read this table
In November 2025 the FDA announced it was initiating removal of boxed warnings from menopausal hormone therapy products, and it approved a first batch of six rewritten labels on 12 February 2026. Manufacturers submit labeling changes for FDA approval; the agency has published no timetable, so which products have updated labels changes over time — which is what this page tracks.
A boxed warning still being present does not mean a label is out of date. The endometrial-cancer boxed warning is retained on systemic estrogen-alone products, so a rewritten label for one of them still carries a boxed warning — covering endometrial cancer only. That is why this table reports what each warning covers rather than whether one exists.
Each row is copied from FDA-published product labeling: retrieved from openFDA, then confirmed against the authoritative label document published by the National Library of Medicine (DailyMed) at the version shown — the warning text quoted above is verified to appear in that document before the row is written. No text here is model-generated or paraphrased.
Label documents are not journal articles: they carry no DOI, are not peer reviewed, and cannot be retracted, so the citation and retraction checks that apply to the study findings elsewhere on this monitor do not apply here. When a product cannot be verified, the table says so instead of guessing. This page is AI-assembled and has not been reviewed by a clinician — it is not medical advice, and a drug’s label is the authority, not this summary of it.
See all 5 findingsOriginal results, comparisons and study details.
1 of 1 source groupsFindings stay together with their study.
SOURCE 015 findings
Cömert, Erhan Hüseyin et al.. Regulatory awareness, counseling priorities, and treatment choices in menopausal hormone therapy: a cross-sectional survey of obstetricians and gynecologists.. Menopause (New York, N.Y.). 2026.
Browse the 1 original sourcesThe full bibliography behind this monitor.
[1]
Cömert, Erhan Hüseyin et al.. Regulatory awareness, counseling priorities, and treatment choices in menopausal hormone therapy: a cross-sectional survey of obstetricians and gynecologists.. Menopause (New York, N.Y.). 2026.
Study findings are generated with AI assistance and have not been reviewed by a clinician. The date on each finding records when it was added to this monitor; it is not the publication date or a clinical review date.
Product-label observations are presented separately from study findings. Each label row identifies the document, version and date checked.
This monitor does not offer individual treatment advice. Bring personal health questions to a qualified clinician.
Get a summary twice a month when this evidence changes
A short summary twice a month, when validated evidence on this topic changes. If nothing changed, we don't email. No marketing. Subscribing covers Menopause, including its related monitor pages.
We'll first send one confirmation email — you're not subscribed until you click it. Subscribing signals an interest in Menopause; we treat that as sensitive: we store only your email address, this topic and the date you subscribed, never linked to any health record, and never sold. Temporary abuse counters use keyed identifiers and expire within 24 hours. Our email provider delivers the messages. Every email includes a one-click unsubscribe link. Sent by ModernDoc (moderndoc.co).